Abstract

Therapy with trastuzumab deruxtecan led to significant improvements in response and overall survival, as compared with standard therapies, among patients with HER2-positive gastric cancer. Myelosuppression and interstitial lung disease were the notable toxic effects. (Funded by Daiichi Sankyo; DESTINY-Gastric01 ClinicalTrials.gov number, NCT03329690.).

Keywords

TrastuzumabMedicineInternal medicineIrinotecanHazard ratioChemotherapyOncologyCancerGastroenterologyPaclitaxelSurgeryConfidence intervalBreast cancerColorectal cancer

Affiliated Institutions

Related Publications

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Harold J. Burstein , Lyndsay N. Harris , P. Kelly Marcom +15 more

Purpose: Trastuzumab-based therapy improves survival for women with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. We conducted a multicenter p...

2003 Journal of Clinical Oncology 343 citations

Publication Info

Year
2020
Type
article
Volume
382
Issue
25
Pages
2419-2430
Citations
1153
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1153
OpenAlex

Cite This

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine , 382 (25) , 2419-2430. https://doi.org/10.1056/nejmoa2004413

Identifiers

DOI
10.1056/nejmoa2004413